Renal Pelvis and Ureter Urothelial Carcinoma Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Renal Pelvis and Ureter Urothelial Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2Phase 3

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Renal Pelvis and Ureter Urothelial Carcinoma
National Cancer Institute (NCI)249 enrolled257 locationsNCT04628767
Recruiting
Not Applicable

A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial

Urothelial CarcinomaBladder CancerUpper Tract Urothelial Carcinoma+1 more
University of Washington128 enrolled1 locationNCT06040762
Recruiting
Phase 4

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Metastatic Bladder Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Metastatic Renal Pelvis and Ureter Urothelial Carcinoma+4 more
Mayo Clinic75 enrolled1 locationNCT06764095
Recruiting
Phase 2

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma
Jonsson Comprehensive Cancer Center21 enrolled1 locationNCT05775471
Recruiting

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Malignant Solid NeoplasmRecurrent Prostate CarcinomaStage IV Bladder Cancer AJCC v7+8 more
University of Washington1,500 enrolled1 locationNCT01050504
Recruiting
Phase 2

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Stage IV Bladder Cancer AJCC v7Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial Carcinoma+3 more
Mayo Clinic70 enrolled1 locationNCT07087860